Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study).

Schäfer G, Hoffmann C, Arasteh K, Schürmann D, Stephan C, Jensen B, Stoll M, Bogner JR, Faetkenheuer G, Rockstroh J, Klinker H, Härter G, Stöhr A, Degen O, Freiwald E, Hüfner A, Jordan S, Schulze Zur Wiesch J, Addo M, Lohse AW, van Lunzen J, Schmiedel S; IDEAL study group.

AIDS Res Ther. 2019 Nov 15;16(1):34. doi: 10.1186/s12981-019-0250-2.

2.

Prescription opiate analgesics, heroin, HIV and HCV among persons who inject drugs in New York City, 2016-2018.

Des Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Perlman DC, Tross S.

Drug Alcohol Depend. 2019 Nov 1;204:107459. doi: 10.1016/j.drugalcdep.2019.04.030. Epub 2019 Aug 30.

PMID:
31521951
3.

Geographic distribution of risk ("Hotspots") for HIV, HCV, and drug overdose among persons who use drugs in New York City: the importance of local history.

Des Jarlais DC, McKnight C, Arasteh K, Feelemyer J, Ross Z, Cooper HLF.

Harm Reduct J. 2019 Sep 2;16(1):53. doi: 10.1186/s12954-019-0326-2.

4.

Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.

Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arastéh K, Hoffmann C, Raffi F, Osiyemi O, Dretler R, Harvey C, Xu X, Plettenberg A, Smith DE, Portilla J, Rugina S, Kumar S, Frobose C, Wan H, Rodgers A, Hwang C, Teppler H.

Antivir Ther. 2019;24(6):425-435. doi: 10.3851/IMP3323.

PMID:
31355775
5.

Injection and Heterosexual Risk Behaviors for HIV Infection Among Non-gay Identifying Men Who Have Sex with Men and Women.

Arasteh K, Des Jarlais DC, McKnight C, Feelemyer J.

AIDS Behav. 2019 Dec;23(12):3315-3323. doi: 10.1007/s10461-019-02551-3.

PMID:
31154560
6.

Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection.

Post G, Shalev N, Baumgarten A, Shimakawa Y, Lemoine M, Krznaric I, Dupke S, Carganico A, Arastéh K, Ingiliz P.

Eur J Gastroenterol Hepatol. 2019 Jun;31(6):723-728. doi: 10.1097/MEG.0000000000001409.

PMID:
30964812
7.

Implementing an Updated "Break the Cycle" Intervention to Reduce Initiating Persons into Injecting Drug Use in an Eastern European and a US "opioid epidemic" Setting.

Des Jarlais D, Uuskula A, Talu A, Barnes DM, Raag M, Arasteh K, Org G, Demarest D, Feelemyer J, Berg H, Tross S.

AIDS Behav. 2019 Sep;23(9):2304-2314. doi: 10.1007/s10461-019-02467-y.

PMID:
30879209
8.

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.

Rockstroh JK, Asmuth D, Pantaleo G, Clotet B, Podzamczer D, van Lunzen J, Arastéh K, Mitsuyasu R, Peters B, Silvia N, Jolliffe D, Ökvist M, Krogsgaard K, Sommerfelt MA.

PLoS One. 2019 Jan 30;14(1):e0210965. doi: 10.1371/journal.pone.0210965. eCollection 2019.

9.

Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use.

Des Jarlais DC, Arasteh K, Feelemyer J, McKnight C, Barnes DM, Perlman DC, Uuskula A, Cooper HLF, Tross S.

Drug Alcohol Depend. 2018 Nov 1;192:74-79. doi: 10.1016/j.drugalcdep.2018.07.034. Epub 2018 Sep 12.

10.

Increased Methamphetamine Use among Persons Who Inject Drugs in Hai Phong, Vietnam, and the Association with Injection and Sexual Risk Behaviors.

Feelemyer J, Duong Thi H, Khuê Pham M, Hoang Thi G, Thi Tuyet Thanh N, Thi Hai Oanh K, Arasteh K, Moles JP, Vu Hai V, Vallo R, Quillet C, Rapoud D, Michel L, Hammett T, Laureillard D, Nagot N, Des Jarlais D; DRIVE Study Team.

J Psychoactive Drugs. 2018 Nov-Dec;50(5):382-389. doi: 10.1080/02791072.2018.1508790. Epub 2018 Sep 5.

11.

Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.

Des Jarlais DC, Cooper HLF, Arasteh K, Feelemyer J, McKnight C, Ross Z.

PLoS One. 2018 Mar 29;13(3):e0194799. doi: 10.1371/journal.pone.0194799. eCollection 2018.

12.

Heterosexual male and female disparities in HIV infection at the end of an epidemic: HIV infection among persons who inject drugs in New York City, 2001-2005 and 2011-2015.

Des Jarlais DC, McKnight C, Feelemyer J, Arasteh K, Tross S, Campbell ANC, Cooper HLF, Perlman DC.

Drug Alcohol Depend. 2018 Apr 1;185:391-397. doi: 10.1016/j.drugalcdep.2017.12.039. Epub 2018 Feb 23.

13.

Using dual capture/recapture studies to estimate the population size of persons who inject drugs (PWID) in the city of Hai Phong, Vietnam.

Des Jarlais D, Khue PM, Feelemyer J, Arasteh K, Thi Huong D, Thi Hai Oanh K, Thi Giang H, Thi Tuyet Thanh N, Vinh VH, Heckathorn DD, Moles JP, Vallo R, Quillet C, Rapoud D, Michel L, Laureillard D, Hammett T, Nagot N.

Drug Alcohol Depend. 2018 Apr 1;185:106-111. doi: 10.1016/j.drugalcdep.2017.11.033. Epub 2018 Feb 2.

14.

Risk Behaviors for HIV and HCV Infection Among People Who Inject Drugs in Hai Phong, Viet Nam, 2014.

Duong HT, Jarlais DD, Khuat OHT, Arasteh K, Feelemyer J, Khue PM, Giang HT, Laureillard D, Hai VV, Vallo R, Michel L, Moles JP, Nagot N; Drive Study Group.

AIDS Behav. 2018 Jul;22(7):2161-2171. doi: 10.1007/s10461-017-1814-6.

15.

Racial/Ethnic Disparities at the End of an HIV Epidemic: Persons Who Inject Drugs in New York City, 2011-2015.

Des Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Tross S, Perlman D, Friedman S, Campbell A.

Am J Public Health. 2017 Jul;107(7):1157-1163. doi: 10.2105/AJPH.2017.303787. Epub 2017 May 18.

16.

HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

Steininger K, Boyd A, Dupke S, Krznaric I, Carganico A, Munteanu M, Neifer S, Schuetze M, Obermeier M, Arasteh K, Baumgarten A, Ingiliz P.

J Viral Hepat. 2017 Oct;24(10):832-839. doi: 10.1111/jvh.12707. Epub 2017 Apr 25.

PMID:
28439936
17.

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.

Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arastéh K, Horsmans Y, Schattenberg JM, Buggisch P, Francque S, Vijgen L, Kakuda TN, Hoeben E, Luo D, Vandebosch A, Jacquemyn B, Van Remoortere P, Verloes R.

BMC Gastroenterol. 2017 Feb 10;17(1):26. doi: 10.1186/s12876-017-0580-2.

18.

Decline in Herpes Simplex Virus Type 2 Among Non-Injecting Heroin and Cocaine Users in New York City, 2005 to 2014: Prospects for Avoiding a Resurgence of Human Immunodeficiency Virus.

Des Jarlais DC, Arasteh K, Feelemyer J, McKnight C, Tross S, Perlman DC, Campbell AN, Hagan H, Cooper HL.

Sex Transm Dis. 2017 Feb;44(2):85-90. doi: 10.1097/OLQ.0000000000000549.

19.

From Long-Term Injecting to Long-Term Non-Injecting Heroin and Cocaine Use: The Persistence of Changed Drug Habits.

Jarlais DC, Arasteh K, Feelemyer J, McKnight C, Barnes DM, Tross S, Perlman DC, Campbell AN, Cooper HL, Hagan H.

J Subst Abuse Treat. 2016 Dec;71:48-53. doi: 10.1016/j.jsat.2016.08.015. Epub 2016 Aug 21.

20.

What happened to the HIV epidemic among non-injecting drug users in New York City?

Des Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Campbell AN, Tross S, Cooper HL, Hagan H, Perlman DC.

Addiction. 2017 Feb;112(2):290-298. doi: 10.1111/add.13601. Epub 2016 Nov 14.

21.

The late-presenting HIV-infected patient 30 years after the introduction of HIV testing: spectrum of opportunistic diseases and missed opportunities for early diagnosis.

Tominski D, Katchanov J, Driesch D, Daley MB, Liedtke A, Schneider A, Slevogt H, Arastéh K, Stocker H.

HIV Med. 2017 Feb;18(2):125-132. doi: 10.1111/hiv.12403. Epub 2016 Aug 1.

22.

Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.

Des Jarlais D, Duong HT, Pham Minh K, Khuat OH, Nham TT, Arasteh K, Feelemyer J, Heckathorn DD, Peries M, Moles JP, Laureillard D, Nagot N; (The Drive Study Team).

AIDS Care. 2016 Oct;28(10):1312-5. doi: 10.1080/09540121.2016.1178698. Epub 2016 May 13.

23.

Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam.

Des Jarlais DC, Thi Huong D, Thi Hai Oanh K, Khuê Pham M, Thi Giang H, Thi Tuyet Thanh N, Arasteh K, Feelemyer J, Hammett T, Peries M, Michel L, Vu Hai V, Roustide MJ, Moles JP, Laureillard D, Nagot N; DRIVE Study Team.

Int J Drug Policy. 2016 Jun;32:50-6. doi: 10.1016/j.drugpo.2016.02.021. Epub 2016 Feb 27.

24.

HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks.

Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K.

AIDS. 2016 Mar 27;30(6):815-26. doi: 10.1097/QAD.0000000000001039. Review.

25.

Consistent Estimates of Very Low HIV Incidence Among People Who Inject Drugs: New York City, 2005-2014.

Des Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Campbell AN, Tross S, Smith L, Cooper HL, Hagan H, Perlman D.

Am J Public Health. 2016 Mar;106(3):503-8. doi: 10.2105/AJPH.2015.303019. Epub 2016 Jan 21.

26.

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.

Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team.

PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016.

27.

Burden and spectrum of infectious disease in Germany 2009-2014: a multicentre study from Berlin's Municipal Hospitals.

Katchanov J, Wöstmann K, Tominski D, Jefferys L, Liedtke A, Schneider A, Slevogt H, Arastéh K, Stocker H.

Infection. 2016 Apr;44(2):187-95. doi: 10.1007/s15010-015-0834-2. Epub 2015 Aug 27.

PMID:
26311655
28.

Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.

Gallant JE, Koenig E, Andrade-Villanueva JF, Chetchotisakd P, DeJesus E, Antunes F, Arastéh K, Rizzardini G, Fehr J, Liu HC, Abram ME, Cao H, Szwarcberg J.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):338-40. doi: 10.1097/QAI.0000000000000598.

29.

[A 55-year old Thai male patient with acute right upper quadrant abdominal pain].

Lindner A, Weber C, Rittweger M, Stocker H, Arastéh K.

Internist (Berl). 2015 Aug;56(8):944-8. doi: 10.1007/s00108-015-3750-8. German.

PMID:
26116106
30.

Will "Combined Prevention" Eliminate Racial/Ethnic Disparities in HIV Infection among Persons Who Inject Drugs in New York City?

Des Jarlais D, Arasteh K, McKnight C, Feelemyer J, Hagan H, Cooper H, Campbell A, Tross S, Perlman D.

PLoS One. 2015 May 12;10(5):e0126180. doi: 10.1371/journal.pone.0126180. eCollection 2015.

31.

Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.

Jordan AE, Des Jarlais DC, Arasteh K, McKnight C, Nash D, Perlman DC.

Drug Alcohol Depend. 2015 Jul 1;152:194-200. doi: 10.1016/j.drugalcdep.2015.03.039. Epub 2015 Apr 13.

32.

Providing ART to HIV Seropositive Persons Who Use Drugs: Progress in New York City, Prospects for "Ending the Epidemic".

Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Hagan H, Cooper HL, Campbell AN, Tross S, Perlman DC.

AIDS Behav. 2016 Feb;20(2):353-62. doi: 10.1007/s10461-015-1028-8.

33.

Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Soliman EZ, Sharma S, Arastéh K, Wohl D, Achhra A, Tambussi G, O'Connor J, Stein JH, Duprez DA, Neaton JD, Phillips A; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:46-54. doi: 10.1111/hiv.12233.

34.

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.

Dieterich D, Nelson M, Soriano V, Arastéh K, Guardiola JM, Rockstroh JK, Bhagani S, Laguno M, Tural C, Ingiliz P, Jain MK, Stern JO, Manero M, Vinisko R, Kort J; STARTVerso4 study group.

AIDS. 2015 Mar 13;29(5):571-81. doi: 10.1097/QAD.0000000000000579.

PMID:
25710287
35.

Neuroimaging of HIV-associated cryptococcal meningitis: comparison of magnetic resonance imaging findings in patients with and without immune reconstitution.

Katchanov J, Branding G, Jefferys L, Arastéh K, Stocker H, Siebert E.

Int J STD AIDS. 2016 Feb;27(2):110-7. doi: 10.1177/0956462415574633. Epub 2015 Feb 18.

PMID:
25693580
36.

Cryptococcosis in HIV-infected hospitalized patients in Germany: Evidence for routine antigen testing.

Katchanov J, Jefferys L, Tominski D, Wöstmann K, Slevogt H, Arastéh K, Stocker H.

J Infect. 2015 Jul;71(1):110-6. doi: 10.1016/j.jinf.2015.01.011. Epub 2015 Jan 30.

PMID:
25644318
37.

State laws, syringe exchange, and HIV among persons who inject drugs in the United States: History and effectiveness.

Bramson H, Des Jarlais DC, Arasteh K, Nugent A, Guardino V, Feelemyer J, Hodel D.

J Public Health Policy. 2015 May;36(2):212-30. doi: 10.1057/jphp.2014.54. Epub 2015 Jan 15.

PMID:
25590514
38.

Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution.

Katchanov J, Blechschmidt C, Nielsen K, Branding G, Arastéh K, Tintelnot K, Meintjes G, Boulware DR, Stocker H.

Int J STD AIDS. 2015 Oct;26(12):912-4. doi: 10.1177/0956462414563630. Epub 2014 Dec 12.

39.

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.

Arribas J, Rizzardini G, Arasteh K, Zurawski C, Dietz C, Pontani D, Garner W, Nguyen T.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19805. doi: 10.7448/IAS.17.4.19805. eCollection 2014.

40.

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.

Raffi F, Rachlis A, Brinson C, Arasteh K, Górgolas M, Brennan C, Pappa K, Almond S, Granier C, Nichols WG, Cuffe RL, Eron J Jr, Walmsley S.

AIDS. 2015 Jan 14;29(2):167-74. doi: 10.1097/QAD.0000000000000519.

41.

Adherence to antiretroviral medications among persons who inject drugs in transitional, low and middle income countries: an international systematic review.

Feelemyer J, Des Jarlais D, Arasteh K, Uusküla A.

AIDS Behav. 2015 Apr;19(4):575-83. doi: 10.1007/s10461-014-0928-3. Review.

42.

Teaching Video NeuroImages: focal cortical myoclonus in progressive multifocal leukoencephalopathy.

Rittweger M, Branding G, Arastéh K, Grosse P, Katchanov J.

Neurology. 2014 Sep 23;83(13):e132. doi: 10.1212/WNL.0000000000000826. No abstract available.

PMID:
25253882
43.

'Time-to-amphotericin B' in cryptococcal meningitis in a European low-prevalence setting: analysis of diagnostic delays.

Katchanov J, von Kleist M, Arastéh K, Stocker H.

QJM. 2014 Oct;107(10):799-803. doi: 10.1093/qjmed/hcu077. Epub 2014 Apr 10.

PMID:
24722846
44.

HIV-associated multicentric Castleman's disease after initiation of antiretroviral therapy: experience of a European centre.

Katchanov J, Zimmermann U, Branding G, Arastéh K, Müller M.

Infection. 2014 Aug;42(4):791-3. doi: 10.1007/s15010-014-0605-5. Epub 2014 Mar 4. No abstract available.

PMID:
24590511
45.

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B.

Lancet Infect Dis. 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11.

46.

A perfect storm: crack cocaine, HSV-2, and HIV among non-injecting drug users in New York City.

Des Jarlais DC, McKnight C, Arasteh K, Feelemyer J, Perlman DC, Hagan H, Dauria EF, Cooper HL.

Subst Use Misuse. 2014 Jun;49(7):783-92. doi: 10.3109/10826084.2014.880176. Epub 2014 Feb 6.

47.

HSV-2 co-infection as a driver of HIV transmission among heterosexual non-injecting drug users in New York City.

Des Jarlais DC, Arasteh K, McKnight C, Perlman DC, Feelemyer J, Hagan H, Cooper HL.

PLoS One. 2014 Jan 31;9(1):e87993. doi: 10.1371/journal.pone.0087993. eCollection 2014.

48.

Use of the "NYC Condom" among people who use drugs.

Des Jarlais DC, McKnight C, Arasteh K, Feelemyer J, Perlman D, Hagan H, Cooper HL.

J Urban Health. 2014 Jun;91(3):547-54. doi: 10.1007/s11524-013-9838-3.

49.

Combined HIV prevention, the New York City condom distribution program, and the evolution of safer sex behavior among persons who inject drugs in New York City.

Des Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Hagan H, Cooper HL, Perlman DC.

AIDS Behav. 2014 Mar;18(3):443-51. doi: 10.1007/s10461-013-0664-0.

50.

Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review.

Feelemyer JP, Jarlais DCD, Arasteh K, Phillips BW, Hagan H.

Drug Alcohol Depend. 2014 Jan 1;134:251-258. doi: 10.1016/j.drugalcdep.2013.10.011. Epub 2013 Oct 24. Review.

Supplemental Content

Loading ...
Support Center